Overview
Nonseminomatous germ cell tumors (NSGCT) are a heterogeneous group of malignancies originating from germ cells, typically found in the testes but can occur extragonadally. They often present with metastatic spread, particularly in advanced stages, requiring aggressive systemic therapy.Diagnosis
Clinical Presentation: Abdominal or testicular mass, often with elevated serum tumor markers (e.g., alpha-fetoprotein, beta-human chorionic gonadotropin) 1.
Imaging: CT or MRI to assess primary tumor and metastatic spread 1.
Biopsy: Histopathological confirmation required for definitive diagnosis 1.
Grading: Utilizes the International Germ Cell Cancer Collaborative Group (IGCCCG) risk stratification system based on primary site, stage, and marker status 1.Management
First-Line Treatment: Bleomycin, etoposide, and cisplatin (BEP) regimen for good-risk metastatic NSGCT 1.
Alternative Regimen: Etoposide and cisplatin (EP) for patients at risk of pulmonary toxicity 1.
Toxicity Management: Consider etoposide-carboplatin as an alternative if severe multiorgan toxicity occurs with cisplatin 1.
Dosing: Standard doses include etoposide 100 mg/m2 1.Special Populations
Elderly Patients: Specific dosing adjustments or alternative regimens may be necessary based on comorbidities and tolerance 1.
Comorbidities: Pulmonary risk may necessitate the use of EP over BEP to avoid bleomycin-induced lung toxicity 1.Key Recommendations
For good-risk metastatic nonseminomatous germ cell tumors, initiate treatment with the BEP regimen (bleomycin, etoposide, cisplatin) 1 (Evidence: Strong).
In patients with pulmonary risk factors, consider etoposide and cisplatin (EP) as a safer alternative 1 (Evidence: Strong).
If severe multiorgan toxicity occurs following cisplatin therapy, etoposide-carboplatin can be a feasible alternative to continue treatment while minimizing toxicity 1 (Evidence: Weak).References
1 Mochizuki T, Sawada N, Nakanishi Y, Kira S, Mitsui T. Severe multiorgan toxicities after the first cycle of standard-dose etoposide-cisplatin therapy for metastatic nonseminoma successfully managed with etoposide-carboplatin: a case report. Journal of medical case reports 2026. link